Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.70 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | NMT1 | P30419 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634794 | 0.89 | KCNH2 (0.59) | SIGMAR1KCNJ1KCNH2SLC6A4 | |
| SCHEMBL14549517 | 0.84 | LTA4H (0.64) | SIGMAR1LTA4H | |
| SCHEMBL15651128 | 0.83 | SIGMAR1 (0.70) | SIGMAR1KCNJ1KCNH2NMT1SLC6A4 | |
| SCHEMBL13858201 | 0.83 | SIGMAR1 (0.70) | SIGMAR1KCNJ1KCNH2NMT1SLC6A4 | |
| SCHEMBL5754907 | 0.83 | SIGMAR1 (0.70) | SIGMAR1KCNJ1KCNH2SLC6A4 | |
| SCHEMBL11630606 | 0.83 | SIGMAR1 (0.70) | SIGMAR1KCNJ1KCNH2NMT1SLC6A4 | |
| SCHEMBL9319743 | 0.83 | SIGMAR1 (0.70) | SIGMAR1KCNJ1KCNH2NMT1SLC6A4 | |
| SCHEMBL10677264 | 0.82 | SIGMAR1 (1.00) | SIGMAR1LTA4H | |
| SCHEMBL457139 | 0.82 | SIGMAR1 (1.00) | SIGMAR1LTA4H | |
| SCHEMBL10900908 | 0.81 | SIGMAR1 (0.67) | SIGMAR1KCNJ1KCNH2NMT1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976525-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20060246099-A1 | Compositions containing piperazine compounds | L'OREAL (FR) | 2006-11-02 | — | — | US | disclosed |
| EP-1099692-B1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6737425-B1 | SUCH AS 1-((4-CYANO-5-METHYL-4-PHENYL)HEXYL)-4-(2-(4-FLUORO -PHENOXY)ETHYL)PIPERAZINE; NERVE SELECTIVE CALCIUM ANTAGONISTS | EISAI CO., LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| CN-1310709-A | N, N-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2001-08-29 | — | — | CN | disclosed |
| EP-1099692-A1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246099-A1 | Compositions containing piperazine compounds | KLF5, CUTA, COL2A1 | SIGMAR1 4633/4885KCNJ1 424/4885KCNH2 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.